Genzyme Corp. will pay Voyager Therapeutics up to $945 million for rights to a variety of treatments for brain diseases including Parkinson’s, Friedreich’s Ataxia and Huntington’s disease.

The price tag includes about $100 million up front, made up of $65 million in cash, and roughly $30 million in equity, plus additional cash depending on various development and sales milestones, should the products ultimately reach the market. As part of the deal, Genzyme gains access to Voyager’s experimental gene therapies for Parkinson’s and Friedreich’s, an inherited disease that causes progressive damage to the nervous system.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.